ArticleMicrobial genomics2019
Unexpected relationships between frequency of antimicrobial resistance, disease phenotype and
Article in Microbial genomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 33 citations in OpenAlex.
- The Complexity of erm-Mediated Resistance: Structural and Functional Perspectives From β-Hemolytic Streptococci.Molecular microbiology · 2026Review
- Machine learning-based discovery of GW3965 as a therapeutic compound against invasive emm92-type group A Streptococcus.npj antimicrobials and resistance · 2026Article
- Before and after the bottleneck: pediatric group A streptococcal infections in Houston, TX, from 2013 to 2023.Microbiology spectrum · 2026Article
- Machine learning-based discovery of GW3965 as a therapeutic compound against invasive emm92-type group A Streptococcus.Research square · 2026Article
- Increase of macrolide resistance amongAntimicrobial agents and chemotherapy · 2025Article
- Molecular Characterization ofMicroorganisms · 2025Article
- Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation.The Lancet. Infectious diseases · 2025Article
- LiaR-dependent gene expression contributes to antimicrobial responses in group AAntimicrobial agents and chemotherapy · 2024Article
- Regulation of erm(T) MLSnpj antimicrobials and resistance · 2024Article
- Article
- Emergence of Erythromycin-Resistant Invasive Group A Streptococcus, West Virginia, USA, 2020-2021.Emerging infectious diseases · 2023Article
- Increases in group A streptococcal infections in the pediatric population in Houston, TX, 2022.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Antibiotic prescribing for adults with group A streptococcal bacteremia in a large healthcare system.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2023Article
- An Overview of Macrolide Resistance in Streptococci: Prevalence, Mobile Elements and Dynamics.Microorganisms · 2022Review
- Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation.Antimicrobial agents and chemotherapy · 2022Article
- The Integrative Conjugative Element ICESpyM92 Contributes to Pathogenicity of Emergent Antimicrobial-ResistantInfection and immunity · 2022Article
- Use of whole-genome sequencing to detect transmission of group AAccess microbiology · 2022Article
- Genomic Characterization of Group A Streptococci Causing Pharyngitis and Invasive Disease in Colorado, USA, June 2016- April 2017.The Journal of infectious diseases · 2022Article
- Characterization of the Type I Restriction Modification System Broadly Conserved among Group A Streptococci.mSphere · 2021Article
- The LiaFSR Transcriptome Reveals an Interconnected Regulatory Network in Group A Streptococcus.Infection and immunity · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Despite universal susceptibility to β-lactams, resistance to second-line antimicrobials (e.g. erythromycin) is increasingly common among group A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.